A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

NCT04456816 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Severe Proteinuria Due to Idiopathic Membranous Nephropathy

Interventions

DRUG: 100 mg AP1189
DRUG: Placebo

Sponsor

SynAct Pharma Aps